Cart
sales@molnova.com
ALK-IN-27
CAS No. 2739866-40-9
ALK-IN-27( —— )
Catalog No. M37318 CAS No. 2739866-40-9
Neladalkib (NVL-655) is a selective and brain-permeable ALK inhibitor with antitumor activity that inhibits a variety of ALK-mutant oncoproteins, and may be useful in the study of non-small cell cancers.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 76 | Get Quote |
|
| 5MG | 118 | Get Quote |
|
| 10MG | 188 | Get Quote |
|
| 25MG | 336 | Get Quote |
|
| 50MG | 512 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameALK-IN-27
-
NoteResearch use only, not for human use.
-
Brief DescriptionNeladalkib (NVL-655) is a selective and brain-permeable ALK inhibitor with antitumor activity that inhibits a variety of ALK-mutant oncoproteins, and may be useful in the study of non-small cell cancers.
-
DescriptionALK-IN-27 (compound 1) is a potent ALK inhibitor. ALK-IN-27 shows antitumor activity. ALK-IN-27 has an IC50 of 2.7 nM for Ba/F3 CLIP1-LTK cell.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetALK
-
RecptorALK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2739866-40-9
-
Formula Weight452.91
-
Molecular FormulaC23H22ClFN6O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(C)N1C2=C(CC=3C(C=4C([C@@H](C)OC=5C=C2C=NC5N)=CC(F)=CC4)=NN(C)C3)C(Cl)=N1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jennifer Anne Green, et al. Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine. WO2023196910A1.
molnova catalog
related products
-
Iruplinalkib
Iruplinalkib (WX-0593) is an orally active, selective and potent ALK and ROS1 tyrosine kinase inhibitor with anticancer activity for use in the study of non-small cell lung cancer.
-
AZ12601011 B
AZ12601011 is an orally active, selective and potent TGFBR1 kinase inhibitor.
-
LDN212854
LDN-212854 is a novel BMP inhibitor that exhibits substantially greater selectivity for BMP versus the TGF-β type I receptors.
